Swiss National Bank lifted its holdings in shares of Editas Medicine Inc (NASDAQ:EDIT) by 11.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 44,800 shares of the company’s stock after buying an additional 4,700 shares during the period. Swiss National Bank owned about 0.10% of Editas Medicine worth $1,377,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Global Thematic Partners LLC grew its position in Editas Medicine by 8.7% during the 4th quarter. Global Thematic Partners LLC now owns 614,052 shares of the company’s stock worth $18,869,000 after acquiring an additional 49,011 shares during the last quarter. State Street Corp grew its position in Editas Medicine by 305.4% during the 2nd quarter. State Street Corp now owns 537,640 shares of the company’s stock worth $9,022,000 after acquiring an additional 405,022 shares during the last quarter. Ark Investment Management LLC grew its position in Editas Medicine by 121.9% during the 2nd quarter. Ark Investment Management LLC now owns 510,187 shares of the company’s stock worth $8,561,000 after acquiring an additional 280,265 shares during the last quarter. Northern Trust Corp grew its position in Editas Medicine by 245.9% during the 2nd quarter. Northern Trust Corp now owns 373,149 shares of the company’s stock worth $6,261,000 after acquiring an additional 265,273 shares during the last quarter. Finally, American Century Companies Inc. bought a new stake in Editas Medicine during the 3rd quarter worth $7,497,000. 72.40% of the stock is owned by institutional investors.
In other Editas Medicine news, CFO Andrew A. F. Hack sold 18,000 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $34.21, for a total value of $615,780.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Katrine Bosley sold 14,995 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $34.15, for a total value of $512,079.25. The disclosure for this sale can be found here. Insiders sold a total of 101,782 shares of company stock worth $3,514,684 in the last quarter. Corporate insiders own 19.40% of the company’s stock.
Shares of Editas Medicine Inc (NASDAQ:EDIT) opened at $41.42 on Wednesday. Editas Medicine Inc has a 52-week low of $13.12 and a 52-week high of $45.02. The company has a current ratio of 9.05, a quick ratio of 9.05 and a debt-to-equity ratio of 0.16.
Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Tuesday, March 6th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.09). Editas Medicine had a negative net margin of 876.49% and a negative return on equity of 61.92%. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $4.25 million. During the same quarter last year, the firm posted ($1.10) EPS. The company’s quarterly revenue was up 311.1% on a year-over-year basis. sell-side analysts anticipate that Editas Medicine Inc will post -3.23 EPS for the current year.
About Editas Medicine
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.